Ultragenyx Pharmaceutical Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
50.18 M |
Public Float |
35.64 M |
Ultragenyx Pharmaceutical Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$6.35 |
Market Cap |
$3.42 B |
Shares Outstanding |
57.47 M |
Public Float |
51.09 M |
Address |
60 Leveroni Court Novato California 94949 United States |
Employees | - |
Website | http://www.ultragenyx.com |
Updated | 07/08/2019 |
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. |